title: An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver.
abstract: Chronic hepatitis C remains a significant medical and economic burden in Canada, affecting nearly 1% of the population. Since the last Canadian consensus conference on the management of chronic hepatitis C, major advances have occurred that warrant a review of recommended management approaches for these patients. Specifically, direct-acting antiviral agents with dramatically improved rates of virological clearance compared with standard therapy have been developed and interferon-free, all-oral antiviral regimens have been approved. In light of this new evidence, an update to the 2012 Canadian Association for the Study of the Liver consensus guidelines on the management of hepatitis C was produced. The present document reviews the epidemiology of hepatitis C in Canada, preferred diagnostic testing approaches and recommendations for the treatment of chronically infected patients with the newly approved antiviral agents, including those who have previously failed peginterferon and ribavirin-based therapy. In addition, recommendations are made regarding approaches to reducing the burden of hepatitis C in Canada.
authors.forename: Robert P
authors.initials: RP
authors.lastname: Myers
authors.forename: Hemant
authors.initials: H
authors.lastname: Shah
authors.forename: Kelly W
authors.initials: KW
authors.lastname: Burak
authors.forename: Curtis
authors.initials: C
authors.lastname: Cooper
authors.forename: Jordan J
authors.initials: JJ
authors.lastname: Feld
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D002170:Canada / Q000453:epidemiology; D000075202:Contraindications; D004359:Drug Therapy, Combination; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D011480:Protease Inhibitors / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D011480:Protease Inhibitors